Tacrine interacts with different sites on nicotinic receptor subtypes in SH-SY5Y neuroblastoma and M10 cells

被引:9
作者
Svensson, AL [1 ]
机构
[1] Huddinge Univ Hosp, Dept Clin Neurosci, Karolinska Inst, Div Mol Neuropharmacol, S-14186 Huddinge, Sweden
关键词
tacrine; H-3]epibatidine; SH-SY5Y cells; M10; cells; nicotinic receptor subtypes; mecamylamine; tubocurarine; chronic treatment;
D O I
10.1016/S0166-4328(00)00213-8
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
The effect of chronic treatment with the cholinesterase inhibitor tacrine on nicotinic receptor subtypes was investigated in human SH-SY5Y neuroblastoma cells and in a fibroblast cell line (M10 cells) stably transfected with alpha 4 beta 2 nicotinic receptors. Tacrine significantly increased the number of nicotinic receptors in SH-SY5Y cells, in a concentration dependent manner (10(-9) to 10(-4) M), when using [H-3]epibatidine as labelled ligand. Chronic tacrine treatment of M10 cells significantly increased and decreased the number of alpha 4 beta 2 nicotinic receptors in a concentration dependent manner (10(-9) to 5 x 10(-6) M and 2 x 10(-5) to 10(-4) M, respectively). The tacrine induced increase of nicotinic receptors in SH-SY5Y cells, was not blocked in the presence of the nicotinic antagonists tubocurarine or mecamylamine. A further increase in the number of nicotinic receptors was, however, observed in the presence of mecamylamine. This study demonstrates that the effect of tacrine on the number of nicotinic receptor subtypes is different in human SH-SY5Y neuroblastoma and M10 cells. The up-regulation of different nicotinic receptor subtypes obtained with tacrine might be achieved through interaction via different binding sites on the receptor, i.e. the acetylcholine binding site as well as an allosteric site. (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:193 / 197
页数:5
相关论文
共 24 条
[1]  
AMBERLA K, 1993, ACTA NEUROL SCAND, V88, P55
[2]   A CONTROLLED TRIAL OF TACRINE IN ALZHEIMERS-DISEASE [J].
FARLOW, M ;
GRACON, SI ;
HERSHEY, LA ;
LEWIS, KW ;
SADOWSKY, CH ;
DOLANURENO, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 268 (18) :2523-2529
[3]  
GERZANICH V, 1995, MOL PHARMACOL, V48, P774
[4]  
Gorbounova O, 1998, J NEUROCHEM, V70, P1134
[5]   Nicotinic receptor stimulation protects neurons against beta-amyloid toxicity [J].
Kihara, T ;
Shimohama, S ;
Sawada, H ;
Kimura, J ;
Kume, T ;
Kochiyama, H ;
Maeda, T ;
Akaike, A .
ANNALS OF NEUROLOGY, 1997, 42 (02) :159-163
[6]   A 30-WEEK RANDOMIZED CONTROLLED TRIAL OF HIGH-DOSE TACRINE IN PATIENTS WITH ALZHEIMERS-DISEASE [J].
KNAPP, MJ ;
KNOPMAN, DS ;
SOLOMON, PR ;
PENDLEBURY, WW ;
DAVIS, CS ;
GRACON, SI ;
APTER, JT ;
LAZARUS, CN ;
BAKER, KE ;
BARNETT, M ;
BAUMEL, B ;
EISNER, LS ;
CASTELLS, B ;
BOLOURI, R ;
BENNETT, D ;
FORCHETTI, C ;
LEVIN, A ;
BLASS, JP ;
NOLAN, KA ;
GAINES, ER ;
RELKIN, N ;
BORISON, RL ;
DIAMOND, B ;
CELESIA, GG ;
ROSS, AP ;
DEXTER, J ;
DOODY, R ;
LIPSCOMB, L ;
KREITER, K ;
DUBOFF, EA ;
BLOCK, P ;
MARSHALL, D ;
WESTERGAARD, N ;
EARL, NL ;
WYNE, SV ;
HINMANSMITH, E ;
FARLOW, M ;
HENDRIE, HC ;
CARESS, JA ;
FARMER, M ;
HARPER, JE ;
FERGUSON, J ;
FOSTER, NL ;
BARBAS, NR ;
BLUEMLEIN, LA ;
GELB, DJ ;
BERENT, S ;
GIORDANI, B ;
GREENWALD, M ;
BERGMAN, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (13) :985-991
[7]   Nicotinic acetylcholine receptors in health and disease [J].
Lindstrom, J .
MOLECULAR NEUROBIOLOGY, 1997, 15 (02) :193-222
[8]   CHARACTERIZATION OF NICOTINIC ACETYLCHOLINE-RECEPTORS EXPRESSED BY CELLS OF THE SH-SY5Y HUMAN NEUROBLASTOMA CLONAL LINE [J].
LUKAS, RJ ;
NORMAN, SA ;
LUCERO, L .
MOLECULAR AND CELLULAR NEUROSCIENCE, 1993, 4 (01) :1-12
[9]   Allosteric modulation of torpedo nicotinic acetylcholine receptor ion channel activity by noncompetitive agonists [J].
Maelicke, A ;
Coban, T ;
Storch, A ;
Schrattenholz, A ;
Pereira, EFR ;
Albuquerque, EX .
JOURNAL OF RECEPTOR AND SIGNAL TRANSDUCTION RESEARCH, 1997, 17 (1-3) :11-28
[10]   EFFICACY OF TACRINE AND LECITHIN IN MILD-TO-MODERATE ALZHEIMERS-DISEASE - DOUBLE-BLIND TRIAL [J].
MALTBY, N ;
BROE, GA ;
CREASEY, H ;
JORM, AF ;
CHRISTENSEN, H ;
BROOKS, WS .
BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6933) :879-883